StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where COO sits in our scored universe today on a single observational measurement. P85 means COO ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $61.21 | $60.00 | -1.98% | 2.2M |
| 05-11 | $60.17 | $58.98 | -1.98% | 1.7M |
| 05-12 | $59.19 | $59.95 | +1.28% | 2.8M |
| 05-13 | $59.46 | $59.47 | +0.02% | 2.2M |
| 05-14 | $59.96 | $60.48 | +0.87% | 0.2M |
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
What drives COO's price movement
Outperforming its sector. Watch for sector rotation and relative momentum shifts.
Outperforming sector peers — leadership position
Highly momentum-driven — trends tend to persist
Moderate news sensitivity
Moderate sentiment influence
Low volume impact — moves on other factors
Low flow signal — not institutional-driven
DNA analysis is based on current factor scoring. Not investment advice.
Quiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.
No sell-side coverage available for COO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Fundamentals not available for COO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-01-31 | Annual 2025 2025-10-31 | Q3 2025 2025-07-31 | Q2 2025 2025-04-30 |
|---|---|---|---|---|
Revenue | $1.02B | $4.09B | $3.03B | $1.97B |
Operating Income | $212.80M | $682.90M | $542.50M | $366.80M |
Net Income | $130.80M | $374.90M | $290.30M | $87.70M |
EPS (Diluted) | $0.66 | $1.87 | $1.45 | $0.96 |
Total Assets | $12.42B | $12.39B | $12.38B | $12.41B |
Total Liabilities | $4.06B | $4.16B | $4.02B | $4.13B |
Cash & Equivalents | $124.90M | $110.60M | $124.90M | $116.20M |
Free Cash Flow OCF − CapEx | $158.70M | $433.70M | $283.80M | $119.30M |
Shares Outstanding | 195.10M | 195.90M | 198.80M | 199.50M |